Annual Report

The report describes UCB's 2015 growth phase, with consolidated revenue of € 3 876 million and 7 788 employees worldwide. It emphasizes the Patient Value Strategy and four main medicines, which accounted for 77% of net sales. The CSR reporting covers Scope 1, Scope 2 and business-travel Scope 3 emissions and reports no work-related fatalities. The CSR Performance Report is stated to be in accordance with GRI G4 Core and includes PwC limited assurance over selected indicators.